SMALLPOX VIRULENCE AND COMPLEMENT REGULATORY PROTEINS
天花毒力和补体调节蛋白
基本信息
- 批准号:7641538
- 负责人:
- 金额:$ 38.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-03-01 至 2009-02-28
- 项目状态:已结题
- 来源:
- 关键词:Active SitesAmericanAmino AcidsBindingBinding SitesBiological AssayCD46 AntigenCD55 AntigensCatalytic DomainCellsComplementComplement 3bComplement 3d ReceptorsComplement 4bComplement ActivationComplement Factor HComplement InactivatorsComplement ReceptorDataData SetEctromeliaEczemaEnzymesExcisionFamilyGene DeletionGoalsGrantHeparin BindingHomologous ProteinHumanHuman ActivitiesImmuneImmune responseImmunityImmunologic Deficiency SyndromesIndividualInfectionInfectious EctromeliaLabelLaboratoriesMaizeMembraneMembrane ProteinsModelingMouse Pox VirusMouse ProteinMouse StrainsMusMutagenesisMutateMutationPathogenesisPlasma ProteinsPositioning AttributePoxviridaePoxviridae InfectionsProteinsPublic HealthPublishingRegulationRelative (related person)ResistanceRoleRussiaSiteSmallpoxSmallpox VaccineStructureSurfaceSystemTransmembrane DomainUnited StatesVaccinesVacciniaVaccinia virus complement-control proteinViralViral ProteinsVirulenceVirulence FactorsVirusZea maysanalogbasecofactorcomplement 4b-binding proteinexperiencefunctional mimicsgenetic regulatory proteingenome sequencinghuman diseasein vivoinhibitor/antagonistmanmembermicroorganismnovelreceptorresearch studytoe corn
项目摘要
Public health concems have emerged regarding use of smallpox as a bioterrorist weapon since most
Americans are no longer immune. Poxviruses subvert the complement system via the expression of
regulatory proteins. In variola, vaccinia and ectromelia, the proteins are called SPICE (for smallpox inhibitor
of complement enzymes), VCP (vaccinia virus complement control protein) and EMICE (an uncharactedzed
analog in ectromelia that we have labeled "ectromelia inhibitor of complement enzymes"). These secreted
virulence factors down-regulate complement activation by mimicking the functional repertoire of a family of
host proteins called the Regulators of Complement Activation (RCA). The viral proteins are also structurally
related to their host counterparts. Specific Aims: 1. To characterize the complement inhibitory profile of
SPICE compared to its human counterparts. We will identify the principal complement-evading activity of
SPICE and this will become a target for neutralization. These assessments will take place with the native
soluble protein as well as after it attaches to cells via either its heparin-binding site(s) or by addition of an
anchor. 2. To determine the complement regulatory sites of SPICE. These experiments will take advantage
of the functional profiles (defined in Aim 1) and the sequences of active sites of RCA proteins that are
homologous to corresponding regions of SPICE, VCP, and EMICE. These two sets of data provide a logical
strategy for a mutational analysis to locate the active sites. 3. To characterize the complement regulatory
activity of EMICE. This mousepox protein has not been evaluated for its complement inhibitory (virulence)
activity. It is about 90% identical to SPICE and VCP. We will first characterize its regulatory activity for
human and mouse complement. Second, we will assess its role in vivo as a virulence factor by infecting
sensitive and resistant mouse strains with the ectromelia virus deleted of its complement regulator. The
proposed experiments should provide novel information relative to the pathogenesis of poxvirus infections of
man and mouse. Additionally, these results will serve as a guide to produce a less toxic small pox vaccine
and to identify a viral target for mAb treatment of variola infection.
由于大多数
美国人不再免疫。痘病毒通过表达来颠覆补体系统
调节蛋白。在Variola,Vaccinia和Ectromelia中,蛋白质称为香料(对于天花抑制剂
补体酶),VCP(Vaccinia病毒补体对照蛋白)和EMITE(未塑性
在胚胎中,我们标记了“补体酶的抑制剂”)。这些分泌
毒力因子通过模仿一个家族的功能库来下调补体激活
宿主蛋白称为补体激活调节剂(RCA)。病毒蛋白在结构上也是
与他们的主机同行有关。具体目的:1。表征补体的抑制作用
与人类对应物相比,香料。我们将确定主要的补体撤回活动
香料,这将成为中和的目标。这些评估将与当地人进行
可溶性蛋白以及之后,它通过其肝素结合位点附着在细胞上或通过添加
锚。 2。确定香料的补体调节位置。这些实验将利用
功能轮廓(在AIM 1中定义)和RCA蛋白的活性位点的序列是
与香料,VCP和Emice的相应区域同源。这两组数据提供了逻辑
突变分析的策略来定位活动位点。 3。表征补体调节
Emice的活性。该菌蛋白的补体抑制(毒力)尚未评估
活动。它与香料和VCP相同约90%。我们首先将其调节活动描述
人和老鼠的补充。其次,我们将通过感染来评估其在体内的作用作为毒力因子
敏感和抗性小鼠菌株具有其补体调节剂缺失的胚胎病毒。这
提出的实验应提供与痘病毒感染的发病机理的新信息
男人和鼠标。此外,这些结果将作为产生毒性较小的小痘疫苗的指南
并确定用于MAB治疗Variola感染的病毒靶标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
John Atkinson其他文献
John Atkinson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('John Atkinson', 18)}}的其他基金
Scleroderma Renal Crisis as a Genetic Complementopathy
硬皮病肾危象是一种遗传性互补病
- 批准号:
10159866 - 财政年份:2020
- 资助金额:
$ 38.97万 - 项目类别:
Defining the Complosome in Human Cells, Tissues and Disease States
定义人类细胞、组织和疾病状态中的复合体
- 批准号:
10597611 - 财政年份:2020
- 资助金额:
$ 38.97万 - 项目类别:
Defining the Complosome in Human Cells, Tissues and Disease States
定义人类细胞、组织和疾病状态中的复合体
- 批准号:
10375425 - 财政年份:2020
- 资助金额:
$ 38.97万 - 项目类别:
Complement Activation Signatures in Systemic Lupus Erythematosus: Castle Study
系统性红斑狼疮中的补体激活特征:Castle 研究
- 批准号:
9317177 - 财政年份:2017
- 资助金额:
$ 38.97万 - 项目类别:
Flavivirus NS-1, complement and disease susceptibility
黄病毒 NS-1、补体和疾病易感性
- 批准号:
7672127 - 财政年份:2009
- 资助金额:
$ 38.97万 - 项目类别:
相似海外基金
Chemical and Structural Approaches to Study Energy Homeostasis Pathways in Cancer and Metabolic Disorders
研究癌症和代谢紊乱能量稳态途径的化学和结构方法
- 批准号:
10682910 - 财政年份:2017
- 资助金额:
$ 38.97万 - 项目类别:
Cela1 Mediates Stretch-regulated Elastin Remodeling During Alveolar Septation
Cela1 介导肺泡间隔期间拉伸调节的弹性蛋白重塑
- 批准号:
9011701 - 财政年份:2016
- 资助金额:
$ 38.97万 - 项目类别:
Cela1 Mediates Stretch-regulated Elastin Remodeling During Alveolar Septation
Cela1 介导肺泡间隔期间拉伸调节的弹性蛋白重塑
- 批准号:
9411003 - 财政年份:2016
- 资助金额:
$ 38.97万 - 项目类别: